gp100: 209-217(210M) Peptide Vaccine
DCTPepD ID DCTPepD0095
Active Ingredients gp100: 209-217(210M) Peptide Vaccine
Description A synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210 designed to improve immunogenicity. Vaccination with gp100:209-217(210M) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing gp100.
Synonyms gp100:209-217(210M); G9 209-2M; Disomotide; MPS-22; gp100: 209-217(210M) Peptide Vaccine; Disomotide; MPS-22
Disease Melanoma, Neoplasm Metastasis
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C47H74N10O14S
Molecular Weight 1035.2
Active Sequence IMDQVPFSV
Sequence Length 9
Modification None
IUPAC Name (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid
InChI InChI=1S/C47H74N10O14S/c1-8-26(6)36(49)45(68)51-29(18-20-72-7)39(62)52-31(22-35(60)61)42(65)50-28(16-17-34(48)59)40(63)55-37(24(2)3)46(69)57-19-12-15-33(57)44(67)53-30(21-27-13-10-9-11-14-27)41(64)54-32(23-58)43(66)56-38(25(4)5)47(70)71/h9-11,13-14,24-26,28-33,36-38,58H,8,12,15-23,49H2,1-7H3,(H2,48,59)(H,50,65)(H,51,68)(H,52,62)(H,53,67)(H,54,64)(H,55,63)(H,56,66)(H,60,61)(H,70,71)/t26-,28-,29-,30-,31-,32-,33-,36-,37-,38-/m0/s1
InChI_Key BDQMCYCLZBSYJZ-BBXCZNCNSA-N
SMILES CC[C@@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(O)=O)=O)CO)=O)CC2=CC=CC=C2)=O)=O)=O)CCC(N)=O)=O)CC(O)=O)=O)CCSC)=O)N)C
External Codes
PubChem CID 657090
DrugBank Accession Number Not available
NCI Thesaurus Code C49022 C76227
UNII 8028PPX4PM GSRS
CAS 181477-43-0
Drug approval
Drug indication
Investigated for use/treatment in Melanoma, Neoplasm Metastasis.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00005949 | Phase II Study of Melanoma Vaccine (NSC #683472/675756, IND #6123) and Low-Dose, Subcutaneous Interleukin-2 in Advanced Melanoma | Recurrent Melanoma; Stage IV Melanoma | Phase 2 | Treatment |
| NCT00020475 | Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma | Extraocular Extension MelanomaRecurrent Intraocular Melanoma | Phase 2 | Treatment |
| NCT00001705 | Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence | Melanoma; Neoplasm Metastasis | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
